Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Antikor Biopharma Limited" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Antikor Biopharma Limited for you to read. Along with our medical data and news we also list Antikor Biopharma Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Antikor Biopharma Limited Companies for you to search.
Biopharma companies are preparing for #climatechange. https://buff.ly/2SUdP6E
SUZHOU, China, Feb. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone") today announced that the National Medical Products Administration (NMPA) recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line treatment against KIT-driven gastrointestinal stromal tumors (GIST). The study will be part of the global VOYAGER Phase II...
Amsterdam, The Netherlands, 15 February 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraor...
Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI...
Hurricanes, power outages, floods, droughts, forest fires — it's all a risk for biopharma companies. Here's how the industry is preparing for climate change. https://buff.ly/2SBxIAd
Hurricanes, power outages, floods, droughts, forest fires — it's all a risk for biopharma companies. Here's how the industry is preparing for climate change.
Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech The post Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML appeared first on Pharmaceutical Business review.
Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech The post Vor Biopharma receives $42m funds to advance development of cell therapy product candidate for acute myeloid leukemia appeared first on Pharmaceutical Business review.
Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors and prepares for a contemplated secondary listing on the First North Stockholm marketplace Herantis Pharma Plc Company release 15 February 2019 at 9:00 am Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japa...
JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:00 a.m. EST at the Lotte New York Palace Hotel, in New York, NY. ...
OCALA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or...
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Experimental Drug Blocks Development of Malignant Melanomas .A promising experimental drug may prevent growth and spread of malignant melanomas having a mutation in the NRAS gene. from Drug … Continue reading →
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Darwin’s rabbit helps to explain the fightback against myxomatosis .Nearly seventy years after myxomatosis decimated the rabbit populations of Australia, Britain and France, a new study reveals how … Continue reading →
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Nimbus brings on Janssen discovery head as CSO with plans to expand its portfolio .Digital drug miner Nimbus Therapeutics has brought on Janssen’s global head of lead discovery, … Continue reading →
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Reprogramming pancreatic cells into insulin makers to treat diabetes .Scientists are keen to find methods for regenerating insulin-producing beta cells to treat diabetes. Now, researchers at the University … Continue reading →
Siddhartha Mukherjee’s Vor Biopharma raises $42m for leukaemia trials
5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunothe
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitments .Axovant has spun off its small molecule team into a new company, … Continue reading →
At today´s meeting, the Supervisory Board of Sartorius AG (FWB:SRT) approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting on March 28, 2019, to pay dividends of 0.62 euro per preference share and 0.61 euro per ordinary share. Prior-year dividends were 0.51 euro and 0.50 euro per preference share...
Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive Investors at the BIO CEO and Investor Conference in New York. The biopharmaceutical company is developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.
Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced the appointments of Patrick Gray and Garry Nicholson to its Board of Directors, serving as independent directors effective immediately. “I am ...
Press release2019-02-14 Martin Åmark, CEO of Xbrane Biopharma AB ("Xbrane"), will as of today also be the Head of IR for Xbrane. The reason for this is that Xbrane's current Head of IR and CFO, Susanna Helgesen, will be on parental leave on a part-time basis for a period. During the parental leave, Susanna Helgesen will remain as CFO. The finance team has also bee...
Vor Biopharma Completes $42M Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia https://www.businesswire.com/news/home/20190213005927/en/Vor-Biopharma-Completes-42-Million-Series-Financing
Vor Biopharma Completes $42M Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia https://www.businesswire.com/news/home/20190213005927/en/Vor-Biopharma-Completes-42-Million-Series-Financing …
Cambridge, UK, 14 February 2019 - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, announces that its operating subsidiary, Feedback Medical Ltd, has appointed Dr Tom Oakley as its Chief Executive Officer. A qualified clinical radiologist, Dr Oakley has significant experience of successfully launching healthcare pr...
US biopharma AbbVie has agreed a deal with Teneobio, a California-based biotech, to develop and commercialize an immunotherapeutic that targets B-cell maturation antigen (BCMA) for treating multiple myeloma, a type of blood cancer. Under the terms of the transaction, AbbVie will pay $90 million upfront to develop Teneobio’s TNB-383B, a bispecific antibody.